Cardiff Oncology, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
CRDF$0.80+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Net loss | $(45,851) | $(45,431) |
| Other comprehensive loss: | ||
| Unrealized gain on securities available- for-sale | 16 | 101 |
| Total comprehensive loss | (45,835) | (45,330) |
| Preferred stock dividend payable on Series A Convertible Preferred Stock | (25) | (24) |
| Comprehensive loss attributable to common stockholders | $(45,860) | $(45,354) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.